- Rhythm Pharmaceuticals Announces New Employment Inducement Grants
- Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
- Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
- Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
- Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
- Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
- Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
- Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
- Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
- Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates
More ▼
Key statistics
On Thursday, Rhythm Pharmaceuticals Inc (RYTM:NMQ) closed at 38.11, -27.51% below its 52-week high of 52.57, set on Feb 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 37.83 |
---|---|
High | 38.90 |
Low | 37.62 |
Bid | 35.00 |
Offer | 37.91 |
Previous close | 38.11 |
Average volume | 509.49k |
---|---|
Shares outstanding | 60.96m |
Free float | 57.37m |
P/E (TTM) | -- |
Market cap | 2.32bn USD |
EPS (TTM) | -3.19 USD |
Data delayed at least 15 minutes, as of Apr 18 2024 21:15 BST.
More ▼